Pharma BD Deal Intelligence
Strong initial integration soured by a decade-long quality crisis, and the whole consumer unit was ultimately spun off into a stock that has underperformed
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
J&J's $16.6B acquisition of Pfizer's consumer health unit reflected drugmakers' search for secure revenue streams amid approaching patent expirations, though…
FTC required divestitures in OTC H-2 blockers (Zantac to Boehringer Ingelheim), hydrocortisone anti-itch, night-time sleep aids, and diaper rash treatments to…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Consumer health (Listerine, Nicorette, Sudafed, Benadryl, Neosporin); borderline - consumer/OTC scope; closed 2006-12-20
Strong initial integration soured by a decade-long quality crisis, and the whole consumer unit was ultimately spun off into a stock that has underperformed
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Pfizer Consumer Healthcare (this deal) | 2006 | $16.6B | 56 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2006 deals · Johnson & Johnson deals · Multiple (undisclosed) deals